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Upregulation of SMYD3 and SMYD3 
VNTR 3/3 polymorphism increase 
the risk of hepatocellular carcinoma
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C.-Thomas Bock  1,5, Heiner Wedemeyer6, Nguyen Linh toan2,4, Mai Hong Bang3, 
peter G. Kremsner1, Christian G. Meyer1,2,7, Le Huu Song2,3 & Thirumalaisamy P. Velavan1,2,7*
SMYD3 (SET and MYND domain-containing protein 3) is involved in histone modification, which 
initiates oncogenesis by activating transcription of multiple downstream genes. To investigate 
associations of variable numbers of tandem repeats (VNTR) variants in the SMYD3 gene promoter, 
SMYD3 serum levels and SMYD3 mRNA expression in hepatitis B virus (HBV) infection and clinical 
progression of related liver disease. SMYD3 VNTRs were genotyped in 756 HBV patients and 297 
healthy controls. SMYD3 serum levels were measured in 293 patients and SMYD3 mRNA expression was 
quantified in 48 pairs of hepatocellular tumor and adjacent non-tumor liver tissues. Genotype SYMD3 
VNTR 3/3 was more frequent among HCC patients than in controls (Padjusted = 0.037). SMYD3 serum 
levels increased according to clinical progression of liver diseases (P = 0.01); HCC patients had higher 
levels than non-HCC patients (P = 0.04). Among patients with SMYD3 VNTR 3/3, HCC patients had 
higher SMYD3 levels than others (P < 0.05). SMYD3 mRNA expression was up-regulated in HCC tumor 
tissues compared to other tissues (P = 0.008). In conclusion, upregulation of SMYD3 correlates with the 
occurrence of HCC and SMYD3 VNTR 3/3 appears to increase the risk of HCC through increasing SMYD3 
levels. SMYD3 may be an indicator for HCC development in HBV patients.
Although effective hepatitis B virus (HBV) vaccines are in use worldwide, HBV-related liver diseases are still a 
major health concern with approximately 257 million chronic infections and 887,000 deaths in 20151. HBV is 
the main cause of primary hepatocellular carcinoma (HCC)2. The risk of HCC development is approximately 
40 times higher in chronic HBV carriers (CHB) than in non-carriers3. Vietnam has a high prevalence of HBV 
infections, ranging from 10–20% in the general population and 20–40% among high-risk groups2,4. As a result, 
Vietnam is one of the countries with a high incidence of HCC with >25,000 new cases reported in 20185,6.
Further to viral factors contributing to cancer development, methylation of histone proteins is an important 
mechanism involved in multiple types of cancers including HCC7,8. Methylation of histone proteins at lysine res-
idues can lead to chromatin remodelling, transcription, and signal transduction9. The SET and MYND domain 
containing proteins (SMYDs) belong to a family of the multi-domain SET-containing histone lysine methyltrans-
ferases and play a crucial role in histone methylation. To date, five SMYD family members have been recognized 
(SMYD1-SMYD5). SMYD3 is the most important member, as several findings have demonstrated its role in 
tumor cell growth and its increased expression in various cancers.
SYMD3 promotes dimethylation and trimethylation of histone H3 lysine 4 (H3K4), which initiates onco-
genesis by activating transcription of multiple downstream target genes10,11. SYMD3 overexpression causes cell 
proliferation, migration and adhesion, whereas suppression by RNAi inhibits cell proliferation and migration, 
indicating that SMYD3 plays an important role in carcinogenesis12–14. SYMD3 was found upregulated in HCC, 
colorectal and in breast and lung cancers12,15,16. In vitro interaction of SMYD3 with HBV has been demonstrated, 
showing that SMYD3 expression was upregulated by hepatitis B x protein (HBx) in HepG2 cells, promoting HCC 
development and clinical progression17. Moreover, SMYD3 is a HBx-interacting protein, and this interaction 
induces activation of the activator protein 1 (AP-1), which increases the risk of HCC formation18,19.
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The common variable number of tandem repeat (VNTR) CCGCC sequence in the SMYD3 promoter region 
is the binding site for the E2F transcription factor 1 (E2F-1) and shown to be a susceptibility factor for human 
malignancies20. It has been suggested that, compared to the genotype containing two copies, the genotype involv-
ing three copies of the CCGCC motif might enhance the binding affinity to E2F-1 and, as a result, promote cancer 
progression by activating transcription of multiple oncogenes such as myc gene (myc), signal transducer and 
activator of transcription 3 (STAT3) and β-catenin (β-cat)14,20,21. Moreover, the VNTR genotype 3/3 was associ-
ated with a higher risk of colorectal cancer, HCC, breast cancer, ovarian cancer and esophageal squamous cell 
carcinoma20,22,23. Particularly in liver diseases, VNTR genotype 3/3 contributed an over 3-fold increased risk of 
HCC in a Japanese and a Chinese population20,24. The present study aimed to investigate the association of VNTR 
polymorphisms in the SMYD3 promoter and SMYD expression with HBV infection and clinical progression of 
HBV-related liver diseases, in particular progression to HCC.
Patients and Methods
Patients. Seven hundred and fifty-six Vietnamese chronic HBV-infected patients enrolled between 2013 and 
2015 at the 108 Military Central Hospital, Hanoi, Vietnam, were recruited. All patients were negative for anti-
bodies for hepatitis C virus (anti-HCV) and antibodies for human immunodeficiency virus (anti-HIV) nor had 
a history of alcohol or drug abuse. Patients were categorized into the subgroups of chronic hepatitis B (CHB) 
without liver cirrhosis (LC) or HCC (n = 246), HBV-related LC patients (n = 174) and HBV-related HCC patients 
(n = 336). The clinical and diagnostic characteristics of the study group have been described previously25. LC 
and HCC patients were further classified according to Child-Pugh scores A, B, and C26 and HCC patients were 
categorized according to the Barcelona Clinic Liver Cancer (BCLC) staging system27. The control group (healthy 
controls; HC) consisted of 297 healthy blood donors. All HCs were HBV surface antigen (HBsAg), anti-HCV and 
anti-HIV negative. Five mls of venous blood were collected from each participant. Serum was stored at −80 °C 
until further use.
In order to determine SMYD3 mRNA expression, pairs of HCC tumor and adjacent non-tumor tissue spec-
imens were obtained from 48 HCC patients who underwent surgery at the 108 Military Central Hospital. The 
tumor stage was scored following the BCLC system28.
Ethics statement. Informed written consent was obtained from all participants after detailed explana-
tion of the study at the time of blood sampling. The study protocol conforms to the ethical guidelines of the 
1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research commit-
tee. The Institutional Review Board of the 108 Military Central Hospital, Hanoi, Vietnam (108MCH/Res/
Epi-HBV-HDV-HEV-D2-14-03-2014) and the Ethics committee of University of Tübingen (206/2012B02) 
approved the study.
SMYD3 VNTR genotyping. Genomic DNA of all participants was isolated from whole blood (DNA puri-
fication kit; Qiagen, Hilden, Germany). The promoter region of the SMYD3 gene was amplified using primers 
SMYD3_F (5′-CGC CTG TCT TCT GCG CAG TCG-3′) and SMYD3_R (5′-CCC GAG AAG GCA GCG GTC 
G-3′). Amplicons underwent DNA sequencing.
Quantification of SMYD3 serum levels by ELISA. Of the 756 patients, 293 individuals were tested for 
SMYD3 serum levels, measured by a commercially available human SMYD3 sandwich ELISA kit (Wuhan Fine 
Biological Technology Co. Ltd, Wuhan City, China). In order to determine SMYD3 concentrations, a standard 
curve was plotted (https://www.curveexpert.net/) based on mean of OD values and the known concentration 
of the standards. Finally, SMYD3 concentrations were interpolated based on the standard curve. The detectable 
range of the kit was 31.25–2000 pg/ml.
Quantification of SMYD3 mRNA by RT-PCR. Total RNA of the liver tissues was extracted with Trizol reagent 
(Life Technologies, Carlsbad, CA, USA), followed by reverse transcription into cDNA (QuantiTect Reverse 
Transcription Kit; Qiagen, Hilden, Germany). SMYD3 mRNA levels were assessed through quantification of 
SMYD3 cDNA by qRT-PCR using SYBR Green PCR master mix (Bioline, Luckenwalde, Germany). The GAPDH 
gene (glyceraldehyde-3-phosphate dehydrogenase) was used as reference. Primer sequences were SMYD3_F: 
5′-GTT GGC CTA TAT CCC AGT ATC TCT TTG CTC -3′, and SMYD3_R: 5′-ACC AGT TAG CAT ATC AGC 
ATC CTT GTC CTG -3′, GAPDH_F: 5′-CCA CCC ATG GCA AAT TCC ATG GCA-3′ and GAPDH_R: 5′-TCT 
AGA CGG CAG GTC AGG TCC ACC-3′. All qRT-PCR reactions were performed in duplicate and repeated 
twice (LightCycler® 480 real-time PCR system; Roche, Basel, Switzerland). The fold change of SMYD3 mRNA 
was normalized based upon the ΔΔCt method against expression of Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH).
Statistical analysis. Chi-square and Fisher´s exact tests were used to test for differences of categorical 
variables. Kruskal-Wallis and Mann-Whitney-Wilcoxon tests were applied to compare quantitative variables. 
Hardy-Weinberg equilibrium was assessed. Binary logistic regression models adjusted for age and gender were 
applied to determine SMYD3 VNTR associations with HBV-related liver diseases. Adjusted odds ratios (OR) with 
95% confidence intervals (CI) were calculated. Paired-samples t-test was used to compare SMYD3 mRNA levels 
in tumor and adjacent non-tumor tissues. A linear regression model was applied to analyze the relationship of 
clinical parameters of patients and SMYD3 levels. Pearson’s correlation coefficient test was used to analyze cor-
relations between SMYD3 levels and clinical parameters. Statistical analyses were performed using SPSS version 
22 (SPSS Statistics, IBM, Armonk, NY, USA) and GraphPad Prism 7 (http://www.graphpad.com). Significance 
was set at P < 0.05.
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Results
Patient characteristics. Demographic, laboratory and clinical parameters of the 1053 study participants 
are summarized in Table 1. In the HC group, the mean age was 43 years (range: 18–69), and majority of HCs 
were male (66.7%). Of the 756 patients, 630 (83.3%) were male; the mean age was 52 years (12–91). The median 
age of patients and the proportion of males increased according to the degree of progression of liver diseases 
(P < 0.0001). As expected, albumin, prothrombin levels and platelet counts were higher among CHB patients 
compared to the other patient subgroups (P < 0.0001). HBV DNA levels did not differ among patient subgroups 
(P = 0.4). Higher total bilirubin and direct bilirubin were observed in LC patients compared to the other groups 
(P < 0.0001). Alpha-fetoprotein (AFP) levels were significantly higher in HCC patients compared to CHB and LC 
patients (P < 0.0001) (Table 1).
SMYD3 VNTRs and HBV-related liver diseases. The allele frequencies and genotype distributions of 
SMYD3 VNTR polymorphisms are given in Table 2. Allele frequencies of VNTR 2 and 3 were 21.7% and 78.3% 
among controls and 12% and 88% in HBV patients, respectively. The three tandem repeat allele (VNTR 3) was 
more prevalent among HBV patients than HCs (OR = 1.4, 95% CI = 1.07–1.86, adjusted P = 0.017,). Genotype 
VNTR 3/3 was observed more frequently in patients compared to HCs (OR = 1.4, 95% CI = 1.02–1.97, adjusted 
P = 0.036). Although the frequencies of VNTRs 2/2 and 2/3 were higher among HCs than in the patient group, 
the differences were not significant.
We compared the distribution of allele and genotype frequencies of the SMYD3 VNTRs in the patient sub-
groups (CHB, LC, HCC) with those in HCs. Genotype VNTR 3/3 occurred more frequently in HCC patients than 
in HCs (OR = 2.9, 95%CI = 1.09–8, adjusted P = 0.037,), while genotype VNTR 2/2 was nearly three times more 
frequent in HCs compared to HCC patients (HCC vs HC, OR = 0.34, 95% CI = 0.13–0.93, adjusted P = 0.036). 
However, no differences were observed in pairwise comparisons between the CHB, LC and HC groups.
We also analyzed associations of SMYD3 VNTR polymorphisms with laboratory parameters of HBV infec-
tion (Alpha-fetoprotein (AFP), aspartate transaminase (AST), alanine aminotransferase (ALT), total and direct 
bilirubin, prothrombin, albumin, viral loads). The levels of these parameters were not different in all patients with 
different SMYD3 VNTR genotypes as well as in patient subgroups (CHB, LC and HCC) (P > 0.05).
SMYD3 serum levels in HBV-related liver diseases. Levels of SMYD3 increased significantly according 
to the progression of liver diseases (Fig. 1A,B). The SMYD3 median was 227.1 pg/mL in CHB patients, 287.3 pg/
mL in LC patients and 311.8 in HCC patients and 292.6 pg/mL in patients with both HCC plus LC (P < 0.05). 
The post-hoc analysis showed a significant difference between the HCC and CHB groups (P = 0.012). A corre-
sponding result was observed when comparing the median of SMYD3 levels in non-HCC and in HCC patients 
(251.1 pg/mL and 311.8 pg/mL, respectively, P = 0.04; Fig. 1D), whereas the median of SMYD3 levels did not 
differ between non-LC and LC individuals (Fig. 1C). These results indicate that SMYD3 plays a role in HCC 
Characteristics
HC 
(n = 297)
HBV patients 
(n = 756) CHB (n = 246) LC (n = 174) HCC (n = 336) P value
Age (years) 43 [16–69] 52 [12–91] 41 [12–85] 56 [20–86] 57 [15–91] <0.0001#
Male (%) 66.7 83.3 75.2 82.8 93.7 <0.0001β
Child-Pugh NA
Child A NA 53/169 249/335
Child B NA 75/169 65/300
Child C NA 41/169 21/335
Missing NA 5 1
Clinical parameters
AST (IU/L) NR 132 [14–6206] 187 [14–6206] 119 [15–1221] 101 [17–983] <0.0001#
ALT (IU/L) NR 132 [8–3390] 222 [9–3390] 82 [8–1426] 72 [11–1095] 0.04#
Total bilirubin (µmol/L) NR 39.1 [4.1–571] 34 [5.5–551] 65.2 [4.1–571] 29.4 [4.3–392] <0.0001#
Direct bilirubin (µmol/L) NR 17.2 [0.4–349] 16.1 [0.7–349] 29.5 [0.4–291] 11.6 [0.4–247.3] <0.0001#
Albumin (g/L) NR 37 [15–48] 42 [25–48] 31.8 [15–47] 37 [15–48] <0.0001#
Prothrombin (% of standard) NR 82 [13–269] 94 [17–267] 60 [13–101] 84 [20–269]
<0.0001#
<0.0001#
WBC (×103/mL) NR 6.6 [1.7–20.5] 6.7 [4.1–13.44] 6.2 [1.7–20.5] 6.8 [2.7–17.9] <0.0001#
RBC(×106/mL) NR 4.5 [1.7–6.8] 4.9 [3.1–6.8] 3.9 [1.9–6.7] 4.5 [1.7–6.8] <0.0001#
PLT (×103/ml) NR 174 [17–441] 218 [66–379] 106 [17–441] 177 [34–432] <0.0001#
HBV DNA (log10 copies/ml) NR 5.1 [1–10] 5.2 [2–10] 5 [1–10] 5.1 [1–9] 0.4#
AFP (IU/L) NR 142 [1–4029] 7.4 [1–250] 40 [1.18–707] 280 [1–4029] <0.0001#
Table 1. Demographic and clinical characteristics of healthy controls and HBV patients. CHB, chronic hepatitis 
B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; HC, healthy control; RBC, red blood cells; WBC, white 
blood cells; PLT, platelets. AST and ALT, aspartate and alanine aminotransferase; AFP, alpha-fetoprotein; NR, 
normal range, NA, not applicable. Values given are medians and ranges. (#) Kruskal-Wallis test (β): chi-square 
test.
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SMYD3 
tandem 
repeat
HC 
n = 297 
(%)
CHB 
n = 246 
(%)
LC 
n = 174 
(%)
HCC 
n = 336 
(%)
CHB + LC 
n = 420 (%)
HBV total 
n = 756 
(%)
CHB vs HC LC vs HC HCC vs HC HBV vs HC
OR(95%CI) P value OR(95%CI) P value OR(95%CI) P value OR(95%CI) P value
Genotypes
VNTR 2/2 21 (7.1) 14 (5.7) 6 (3.4) 7 (2.1) 20 (4.8) 27 (3.6) Reference Reference Reference Reference
VNTR 2/3 64 (21.5) 37 (15) 29 (16.7) 61 (18.2) 66 (15.7) 127 (16.8) 0.75 (0.32–1.76) 0.5
1.8 
(0.59–5.6) 0.3
2.7 
(0.89–7.92) 0.079
1.2 
(0.58–2.44) 0.6
VNTR 3/3 212 (71.4) 195 (79.3) 139 (79.9) 268 (79.8) 334 (79.5) 602 (79.6) 1.2 (0.6–2.6) 0.5 2.2 (0.81–6.12) 0.1 2.9(1.07–8) 0.037
1.7 
(0.88–3.15) 0.1
Allele
VNTR 2 106 (21.7) 65 (13.2) 41 (11.8) 75 (11.2) 106 (12.6) 181 (12) Reference Reference Reference Reference
VNTR 3 488 (78.3) 427 (86.8) 307 (88.2) 597 (88.8) 734 (87.4) 1331 (88) 1.4 (0.97–1.92) 0.078 1.5 (1–2.38) 0.05 1.5 (1–2.14) 0.05
1.4 
(1.07–1.86) 0.017
Dominant
VNTR 
2/2&2/3 85 (28.6) 51 (20.7) 35 (20.1) 68 (20.2) 86 (20.5) 154 (20.4) Reference Reference Reference Reference
VNTR 3/3 212 (71.4) 195 (79.3 139 (79.9) 268 979.8) 334 (79.5) 602 (79.6) 1.5 (0.99–2.23) 0.057
1.4 
(0.88–2.4) 0.1
1.3 
(0.86–2.05) 0.2
1.4 
(1.02–1.97) 0.036
Recessive
VNTR 2/2 21 (7.1) 14 (5.7) 6 (3.4) 7 (2.1) 20 (4.8) 27 (3.6) Reference Reference Reference Reference
VNTR 
2/3&3/3 276 (92.9) 232 (94.3) 168 (96.6) 329 (97.9) 400 (95.2) 729 (96.4
1.1 
(0.55–2.35) 0.7
2.2 
(0.8–6.02) 0.1
2.9 
(1.07–8.03) 0.036
1.6 
(0.82–2.94) 0.2
Table 2. Association of the variable number of tandem repeats of SMYD3 with HBV-related liver diseases. 
CHB, chronic hepatitis B; LC, liver cirrhosis; HCC, hepatocellular carcinoma; HC, healthy controls; n, numbers 
individuals; OR, Odd ratio. P values were calculated using binary logistic regression model adjusted for age and 
gender. Bold values reflect statistical significance.
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Figure 1. Association of the SMYD3 serum levels with HBV related liver diseases. The comparison of SMYD3 
levels (A) among healthy controls and groups of patients according to HBV-related diseases, CHB, chronic 
hepatitis B; LC, liver cirrhosis without HCC; HCC, hepatocellular carcinoma; (B) between CHB patients 
with advanced stages patients (including LC and HCC), (C) between patients with and without cirrhosis, (D) 
between patients with and without HCC. Box-plots illustrate medians with 25 and 75 percentiles with whiskers 
to 10 and 90 percentiles; P value were calculated by using Kruskal-Wallis test or Mann-Whitney-Wilcoxon test.
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development. When analyzing the correlation of SMYD3 serum levels with the laboratory parameters in all 
HBV patients and in patient subgroups, SMYD3 serum levels did not correlate with these parameters in all HBV 
patients and in the subgroups.
SMYD3 VNTRs and SMYD3 serum levels and progression of HBV-related liver diseases. We 
analyzed the relationship between SMYD3 VNTR genotypes and SMYD3 serum levels in HBV patients (Fig. 2). 
SMYD3 levels in patients with SMYD3 genotype 3/3 were similar to that in patients with genotypes 2/2 or 2/3 
(P > 0.05, Fig. 2A). In the HCC group, patients with genotype VNTR 3/3 had higher SMYD3 levels than those 
with genotypes VNTR 2/2 and 2/3 (P = 0.03, Fig. 2B). This was not observed in CHB and LC patients (Fig. 2B). 
In addition, in patients with genotypes 2/2 and 2/3 the levels of SYMD3 did not differ between the CHB, LC and 
HCC groups. However, patients with genotype VNTR 3/3 had increased SMYD3 serum levels according to the 
progression of liver diseases (HCC vs. CHB: P = 0.0005, LC vs. CHB: P = 0.036, Fig. 2B). These results indicate 
that genotype VNTR 3/3 may increase SMYD3 levels and, thus, increase the risk of HCC development.
SMYD3 mRNA expression in HCC. In order to examine whether SMYD3 mRNA is upregulated in cancer 
stages as seen in other cancers14,15, we analyzed the expression of SMYD3 mRNA in HCC tissue specimens and 
in adjacent non-tumor liver tissues obtained from 48 HBV-related HCC patients. Expression of SMYD3 mRNA 
in tumor tissues was significantly higher than that in adjacent non-tumor tissues (P = 0.008, Fig. 3A). We then 
examined whether SMYD3 mRNA expression was associated with development of HCC by correlating SMYD3 
mRNA expression with BCLC stages. SMYD3 mRNA expression was higher in stage-B tumor tissues compared 
to that in stage-A tissues (Fig. 3B). A similar trend was seen when SMYD3 mRNA expression was compared 
between non-tumor tissues obtained from stage-A and stage-B HCC patients; however, the difference did not 
reach significance (Fig. 3C). These results indicate that SMYD3 expression is associated with HBV-related HCC.
Discussion
HBV infection is a major cause of HCC. In Vietnam, the prevalence of HBV infection is over 10% in the general 
population1,5. Further to HBV, other factors contributing to the development of HCC include epigenetic changes 
such as methylation and histone modifications of regulatory genes7,8,25. SMYD3, a histone H3-K4 specific methyl-
transferase, is an example of histone modification which is considered a crucial epigenetic factor contributing to 
the development of various human cancers, including liver cancer12,15. So far, the role of SYMD3 and its encoding 
gene SYMD3 in HBV-related liver diseases is not clear. We studied the association of genetic variation and expres-
sion of variant SYMD3 VNTRs with susceptibility to HBV infection and with liver disease progression. We show 
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Figure 2. Association of the VNTRs of SMYD3 with SMYD3 serum levels in HBV-related liver diseases. 
Comparison of the SMYD3 serum levels among healthy controls and patients with HBV-related liver diseases 
who carry different SMYD3 VNTR genotypes. CHB, chronic hepatitis B, LC, liver cirrhosis without HCC, 
HCC, hepatocellular carcinoma. (A) Among healthy controls and HBV patients, (B) among healthy controls 
and patient subgroups including CHB, LC and HCC patients, Box-plots illustrate medians with 25 and 75 
percentiles with whiskers to 10 and 90 percentiles; P values were calculated by using Mann-Whitney-Wilcoxon 
test or Kruskal-Wallis test.
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that both SMYD3 VNTRs in the promoter region and SYMD3 overexpression are associated with HBV-related 
HCC.
SMYD3 VNTR variability has been reported to be a significant factor in HCC20,24. An earlier study has 
reported that VNTR 3/3 homozygosity conferred an over 3-fold increased risk of HCC in a Japanese population20. 
Accordingly, a study in a Chinese population found that the frequency of the SMYD3 VNTR 3/3 genotype was 
higher in HCC patients than in controls24. Consistent with these studies, we observed that the frequencies of the 
SMYD3 VNTR three repeat allele and the 3/3 genotype was higher in HBV patients than in controls (Table 2). 
Further analysis showed that in the HCC group the SMYD3 repeat 3/3 genotype was more frequent than in HCs 
(OR = 2.9, P < 0.05, Table 2). Notably, Wang et al.29 did not find an association between the risk of HCC and the 
three tandem repeat allele.
The SMYD3 VNTRs have been shown to be a susceptibility factor for human cancers, especially for colorec-
tal cancer, breast cancer and HCC20. We observed that the SMYD3 VNTR 3/3 genotype increases the risk of 
HBV-related HCC. A possible explanation is that SMYD3 VNTR 3/3 can effectively promote its affinity with E2F-
1, which is considered an important transcription factor stimulating cellular proliferation and cell cycle progres-
sion20,30,31. In HCC development, overexpression of SMYD3 was previously found in distinct cell lines17,32, and in 
HCC tumors33. However, an association between SMYD3 serum levels and HCC has not been shown so far. In 
our study, SMYD3 serum levels were significantly increased according to the various HBV-related liver disease 
stages. SMYD3 levels were higher in advanced liver disease (LC, HCC) compared to CHB, and HCC patients 
had higher SMYD3 levels than non-HCC patients. These findings indicate that increased SMYD3 levels may be 
associated with the occurrence of HCC, and SMYD3 serum levels may be considered a potential marker for HCC. 
Moreover, SMYD3 serum levels in HCC patients with the SMYD3 VNTR genotype 3/3 were higher than in those 
with genotypes 2/2 and 2/3; this difference was not observed in CHB and LC patients.
Finally, we assessed SMYD3 mRNA expression in liver tissues. In vitro evidence indicates that SMYD3 expres-
sion is up-regulated in HCC cell lines12,32. SMYD3 expression was analyzed in HCC tissues, and upregulation was 
significantly associated with an unfavourable prognosis of HCC33,34. SMYD3 mRNA expression was upregulated 
in HCC tumor compared to adjacent non-tumor tissues, providing further evidence of a role of SMYD3 in HCC 
development. Several studies have shown that SMYD3 can interact with the HBV-HBx protein, which can induce 
upregulation of SMYD3 in HCC, these interactions promote the development of HCC by regulating ERK- and 
AKT/GSK-3β signaling pathways17–19,35. The SMYD3 VNTR polymorphisms might regulate HCC development 
Figure 3. SMYD3 mRNA expression in liver specimens from 48 HCC patients. Relative quantitative real-time 
PCR analysis of SMYD3 mRNA levels. (A) Relative SMYD3 mRNA expression in tumor tissues and in adjacent 
non-tumor tissues. (B) The fold changed SMYD3 mRNA levels between the group of stage A-HCC patients and 
the group of stage B-HCC patients, (C) SMYD3 mRNA expression in stage-A and stage-B tumor tissues and in 
adjacent non-tumor tissues. P values were calculated by using Mann-Whitney-Wilcoxon test. Data are shown as 
mean values with 95% confidence intervals.
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possibly by increased SMYD3 expression in the liver. A recent study has shown that SMYD3 may interact with 
cyclin-dependent kinase 2 (CDK2) and matrix metallopeptidase 2 (MMP2), which are involved in controlling cell 
cycle, proliferation and invasion of hepatocytes, and thus contributing to the tumorigenicity of HCC33. SMYD3 
was also associated with ankyrin repeat and KH domain-containing protein 1 (ANKHD1) that regulate the ini-
tiation, progression and metastasis in HCC36 Although our data underline the significance of the SMYD3 VNTR 
3/3 genotype and SMYD3 overexpression in HBV-related HCC development, the interaction between HBV and 
SYMD3 needs to be investigated further.
In conclusion, our study shows the association of the SMYD3 VNTR 3/3 as well as upregulation of SMYD3 
serum levels and mRNA expression with HCC development, suggesting that SYMD3 has some potential for the 
prediction of HCC in HBV patients.
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